FY2024 Earnings Forecast for NKTR Issued By HC Wainwright

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for Nektar Therapeutics in a research report issued to clients and investors on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings of ($0.46) per share for the year. HC Wainwright currently has a "Buy" rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q4 2024 earnings at $0.13 EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.15) EPS.

Several other brokerages also recently commented on NKTR. Piper Sandler began coverage on Nektar Therapeutics in a research note on Monday, November 4th. They issued an "overweight" rating and a $7.00 target price for the company. BTIG Research restated a "buy" rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.10.

Nektar Therapeutics Trading Down 2.0 %

Shares of NASDAQ NKTR traded down $0.02 during mid-day trading on Thursday, hitting $1.00. The company had a trading volume of 2,159,178 shares, compared to its average volume of 1,799,842. Nektar Therapeutics has a 1 year low of $0.46 and a 1 year high of $1.93. The company has a market capitalization of $184.46 million, a price-to-earnings ratio of -1.19 and a beta of 0.57. The stock's 50-day moving average price is $1.22 and its 200-day moving average price is $1.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NKTR. Samlyn Capital LLC purchased a new position in Nektar Therapeutics in the second quarter worth $11,728,000. Eventide Asset Management LLC lifted its stake in Nektar Therapeutics by 24.8% during the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company's stock worth $12,220,000 after purchasing an additional 1,870,904 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company's stock worth $5,778,000 after purchasing an additional 1,674,924 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Nektar Therapeutics by 66.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company's stock worth $5,096,000 after purchasing an additional 1,634,046 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Nektar Therapeutics during the 2nd quarter valued at about $1,037,000. 75.88% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.